cimb-logo

Journal Browser

Journal Browser

Applications of Natural and Pseudo-Natural Products in Drug Discovery and Development 2025

A special issue of Current Issues in Molecular Biology (ISSN 1467-3045). This special issue belongs to the section "Bioorganic Chemistry and Medicinal Chemistry".

Deadline for manuscript submissions: 31 December 2025 | Viewed by 78

Special Issue Editor


E-Mail Website
Guest Editor

Special Issue Information

Dear Colleagues,

Natural products (NPs) and NP-based semi-synthetic compounds have been attracting increased attention from the scientific community due to their great structural and chemical diversity. Notably, NP-based molecules are valid sources of drug lead compounds, because 60% of chemotherapeutic agents originate from natural products. On the other hand, pseudo‐natural products (PNPs) combine natural product (NP) fragments in novel and intriguing arrangements that are not accessible via biosynthesis pathways. Moreover, they can be regarded as non‐biogenic fusions of NP‐derived fragments. Scientists have established new synthesis principles to advance beyond the chemical space explored by nature by combining the principles of biology-orientated synthesis (BIOS) and fragment-based compound design. Interestingly, scaffolds from different NPs can be combined and reconnected to create new alternative molecular scaffolds: so-called pseudo-natural products.

The aim of this Special Issue on natural product (NP)- and pseudo‐natural product (PNP)-based drug discovery is to underline the most recent discoveries and progress in all fields of biological sciences dealing with NPs and PNPs. This Special Issue will mainly focus on biological studies on NPs and PNPs on a molecular level. In addition, this Special Issue will also focus on the development of new NP- and PNP-based therapeutic agents for the treatment of numerous diseases, employing the newest techniques in pharmacology, biotechnology, and genetic engineering. For this Special Issue, we welcome original articles, communications, and reviews exploring drug discovery and development.

Dr. Hidayat Hussain
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Current Issues in Molecular Biology is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2200 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • natural products
  • pseudo-natural products
  • drug discovery
  • molecular level
  • in vitro studies
  • in vivo studies
  • computational methods
  • mode of action
  • computational methods

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Research

9 pages, 635 KiB  
Article
Osteogenic Potential of Osteolforte: Gene and Protein-Level Evaluation in Human Bone Marrow Stromal Cells
by Da-Sol Kim, Soo-Kyung Bae, Yeon-Ju Kwak, Geum-Joung Youn and Hye-Ock Jang
Curr. Issues Mol. Biol. 2025, 47(8), 588; https://doi.org/10.3390/cimb47080588 - 24 Jul 2025
Abstract
Osteolforte, a compound with potential bone-regenerative properties, was investigated for its effects on human bone marrow stromal cells (hBMSCs). This study aimed to evaluate its impact on cell viability, osteogenic differentiation, and both gene and protein expression using a combination of assays, [...] Read more.
Osteolforte, a compound with potential bone-regenerative properties, was investigated for its effects on human bone marrow stromal cells (hBMSCs). This study aimed to evaluate its impact on cell viability, osteogenic differentiation, and both gene and protein expression using a combination of assays, including CCK-8, Alizarin Red S staining, Quantitative Real-Time PCR (qRT-PCR), and Western blot analysis. The results demonstrated that Osteolforte significantly enhanced osteogenic differentiation in hBMSCs. Alizarin Red S staining revealed increased mineralization, indicating elevated calcium deposition. Gene expression analysis showed an upregulation of key osteogenic markers, including runt-related transcription factor-2 (RUNX-2), collagen type I (COL-1), and bone morphogenetic protein-2 (BMP-2), supporting the role of Osteolforte in promoting osteoblastic activity. In particular, the elevated expression of RUNX-2—a master transcription factor in osteoblast differentiation along with COL-1, a major bone matrix component, and BMP-2, a key bone morphogenetic protein—highlights the compound’s osteogenic potential. In conclusion, Osteolforte enhances early-stage osteogenesis and mineralization in hBMSCs and represents a promising candidate for bone regeneration. Full article
Show Figures

Figure 1

Back to TopTop